Search Results - Frede Donskov

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. by Meixiao Shen, Pingping Hu, Frede Donskov, Guanghui Wang, Qi Liu, Jiajun Du

    Published in PLoS ONE (2014-01-01)
    Get full text
    Article


  2. 2

    Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma by Aska Drljevic-Nielsen, Finn Rasmussen, Jill R. Mains, Kennet Thorup, Frede Donskov

    Published in Translational Oncology (2020-10-01)
    Get full text
    Article


  3. 3

    Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol by Jakob N. Henriksen, Charlotte U. Andersen, Frede Donskov, Elke Hoffmann-Lücke, Eva Greibe, Niels Fristrup

    Published in Acta Oncologica (2025-06-01)
    Get full text
    Article


  4. 4

    Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial by Laura Iisager, Johanne Ahrenfeldt, Frede Donskov, Börje Ljungberg, Axel Bex, Lars Lund, Iben Lyskjær, Niels Fristrup

    Published in BMC Cancer (2024-02-01)
    Get full text
    Article


  5. 5

    Therapies in Refractory Metastatic Renal Cell Carcinoma by Stephanie Berg, Martin Angel, Kathryn E. Beckermann, Frede Donskov, Chung-Han Lee, Pavlos Msaouel, Rana R. McKay, Tian Zhang

    Get full text
    Article


  6. 6

    Involving patient partners as appraisers of shared decision making: an explanatory sequential mixed-methods study by Bettina Mølri Knudsen, Mette Byg Josefsen, Mona Muusmann Petersen, Poul Risom, Henriette Witte Nielsen, Frede Donskov, Stine Rauff Søndergaard, Karina Dahl Steffensen, Dawn Stacey, Lea Lund

    Published in Research Involvement and Engagement (2026-06-01)
    Get full text
    Article


  7. 7

    Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma by Chung-Wei Lee, Thomas Powles, Sabina Signoretti, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang

    Published in Journal for ImmunoTherapy of Cancer (2022-12-01)
    Get full text
    Article


  8. 8

    Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Rena... by Chun Loo Gan, Shaan Dudani, J. Connor Wells, Frede Donskov, Sumanta K. Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly‐Khan A. Lalani, Aaron Hansen, Bernadett Szabados, Guillermo deVelasco, Ben Tran, Jae Lyun Lee, Ulka N. Vaishampayan, Georg A. Bjarnason, Mathushan Subasri, Toni K. Choueiri, Daniel Y. C. Heng

    Published in Cancer Medicine (2021-02-01)
    Get full text
    Article


  9. 9

    Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random... by Howard Gurney, Thomas Powles, Asim Amin, Bohuslav Melichar, Camillo Porta, David F McDermott, Toni K Choueiri, Marc-Oliver Grimm, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Hans J Hammers, Saby George, Robert J Motzer, Alain Ravaud, Osvaldo Arén Frontera, Frede Donskov, Philippe Barthélémy, Viktor Grünwald, Victoria Neiman, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Raya Leibowitz-Amit, Poul F Geertsen, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir

    Published in Journal for ImmunoTherapy of Cancer (2020-10-01)
    Get full text
    Article


Search Tools: